<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715091</url>
  </required_header>
  <id_info>
    <org_study_id>ENRADAS-01</org_study_id>
    <secondary_id>EUDA-CT: 2007-007637-39</secondary_id>
    <nct_id>NCT00715091</nct_id>
  </id_info>
  <brief_title>Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis</brief_title>
  <acronym>ENRADAS</acronym>
  <official_title>Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, controlled, multi-centre clinical trial on AS patients. Experimental&#xD;
      intervention: continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren&#xD;
      Resinate), divided into 75mg Voltaren twice dailyControl intervention: treatment on-demand&#xD;
      (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment&#xD;
      strategy of the control intervention (on-demand) reflects current clinical practice in AS.&#xD;
      Duration of intervention per patient: 2 years Follow-up per patient: safety assessment 3&#xD;
      months after termination of the trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ankylosing spondylitis (AS) is a common chronic inflammatory rheumatic disease with a&#xD;
      prevalence of about 0.5%. First symptoms normally occur in young adulthood. Early in its&#xD;
      course, AS is dominated by chronic pain, fatigue and morning stiffness, later on by ankylosis&#xD;
      and loss of function. Nonsteroidal anti-inflammatory drugs (NSAID) and tumor necrosis factor&#xD;
      (TNF) alpha blocking agents are the only drugs with proven efficacy for signs and symptoms.&#xD;
      It is not clear, however, whether these drugs are also capable of retarding or stopping&#xD;
      structural damage, i.e. prevention of bony ankylosis. Earlier investigations indicated that&#xD;
      NSAIDs have, in addition to their anti-inflammatory, also an anti-osteoproliferative effect.&#xD;
      In this study we will investigate whether treatment with 150 mg diclofenac, a non-selective&#xD;
      NSAID, on a daily basis (continuous treatment) over 2 years is capable to slow down the&#xD;
      development of bony ankylosis as compared to treatment with 75-150mg diclofenac as needed&#xD;
      according to clinical symptoms (on-demand treatment). In this national multi-centre&#xD;
      randomized trial patients with symptomatic AS and indication for NSAID therapy will be&#xD;
      enrolled in about 40 centres. The primary outcome parameter is the proportion of patients&#xD;
      with radiographic progression in the spine after 2 years in each treatment arm. If continuous&#xD;
      NSAID treatment results in less radiographic progression as compared to on-demand treatment,&#xD;
      a true disease modifying effect of NSAID has to be assumed which will most likely change the&#xD;
      place of NSAID treatment in AS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>radiographic change (mean) of the spine after 2 years in the per-protocol population. Radiographs will be collected and centrally digitized. Scoring will be done by 2 readers who were blinded to treatment and sequence of the films</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportions of patients with any progression (change in the mSASSS ≥ 1) and change in the mSASSS &gt; smallest detectable change (SDC), i.e. change in mSASSS which is greater than the measurement error.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITT analysis of radiographic change.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VAS back pain, BASDAI, BASFI, BASMI, CRP.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rates of serious and non-serious adverse events will be documented and compared between the two groups.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclophenac</intervention_name>
    <description>continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>voltaren resinat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclophenac</intervention_name>
    <description>treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Voltaren resinate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AS according to mod. New York criteria&#xD;
&#xD;
          -  Patients must have radiographic damage (at least one syndesmophyte) of the spine but&#xD;
             no complete ankylosis of the cervical and lumbar spine (these are patients at risk for&#xD;
             further and more rapid radiographic progression)&#xD;
&#xD;
          -  Patients must have active disease at inclusion defined as BASDAI question 2 (related&#xD;
             to back pain) &gt;= 4 (VAS, range 0-10) without NSAID treatment and with a clinical&#xD;
             indication for NSAID therapy based on signs and symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No radiographic damage (syndesmophyte) of the spine at baseline&#xD;
&#xD;
          -  Complete ankylosis of the cervical and lumbar spine&#xD;
&#xD;
          -  Inactive disease&#xD;
&#xD;
          -  Evidence of current or past peptic ulcer&#xD;
&#xD;
          -  Current or past coronary heart disease&#xD;
&#xD;
          -  Stroke or transient ischemic attack&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Chronic renal failure (creatinine &gt; 1.5mg/dl)&#xD;
&#xD;
          -  Impaired liver function&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Abnormal liver function (2x upper limit of normal)&#xD;
&#xD;
          -  Active hepatitis B or C, chronic or acute heart failure (NYHA III or IV) -&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  History of neoplastic disease (details please refer to exclusion criteria)&#xD;
&#xD;
          -  History of abuse of &quot;hard&quot; drugs or alcoholism&#xD;
&#xD;
          -  Concomitant treatment with steroids, TNF-blockers, other DMARDs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Rudwaleit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joachim Sieper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jürgen Braun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumazentrum Ruhrgebiet, Herne, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Innere Medizin</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>1072076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Jacki</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Manger</name>
      <address>
        <city>Bamberg</city>
        <state>Bayern</state>
        <zip>96047</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Ochs</name>
      <address>
        <city>Bayreuth</city>
        <state>Bayern</state>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kellner</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiszentrum St. Bonifazius</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81541</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Göttl</name>
      <address>
        <city>Passau</city>
        <state>Bayern</state>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim</name>
      <address>
        <city>Bad Bentheim</city>
        <state>Niedersachsen</state>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Rockwitz</name>
      <address>
        <city>Goslar</city>
        <state>Niedersachsen</state>
        <zip>38640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. von Hinüber</name>
      <address>
        <city>Hildesheim</city>
        <state>Niedersachsen</state>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Gauler</name>
      <address>
        <city>Osnabrück</city>
        <state>Niedersachsen</state>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Dockhorn</name>
      <address>
        <city>Weener</city>
        <state>Niedersachsen</state>
        <zip>26828</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum DüsseldorfKlink für Endokrinologie, Diabetologie und Rheumatologie</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40001</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpraxis</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Ratingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kramer</name>
      <address>
        <city>Remscheid</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42897</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schoo</name>
      <address>
        <city>Rheine</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Praxis Dr. Spieler</name>
      <address>
        <city>Zerbst</city>
        <state>Sachsen-Anhalt</state>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandt</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Mielke</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Zinke</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Schwenke</name>
      <address>
        <city>Dresden</city>
        <zip>01109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Pick</name>
      <address>
        <city>Grafschaft bei Bad Neuenahr-Ahrweiler</city>
        <zip>53501</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kühne</name>
      <address>
        <city>Haldensleben</city>
        <zip>39340</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet, St. Josefs Krankenhaus</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Krankenhaus, Rheumatologie</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kapelle</name>
      <address>
        <city>Hoyerswerda</city>
        <zip>02977</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Kolitsch</name>
      <address>
        <city>Katzhütte</city>
        <zip>98746</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Gräßler</name>
      <address>
        <city>Pirna</city>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Bohl-Bühler</name>
      <address>
        <city>Potsdam</city>
        <zip>14469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Wanders A, Heijde Dv, Landewé R, Béhier JM, Calin A, Olivieri I, Zeidler H, Dougados M. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005 Jun;52(6):1756-65.</citation>
    <PMID>15934081</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>August 22, 2014</last_update_submitted>
  <last_update_submitted_qc>August 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>J. Sieper</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>NSAIDS</keyword>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>SpA</keyword>
  <keyword>Spondyloarthritis</keyword>
  <keyword>radiographic changes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

